Alfuzosin is an α1 receptor antagonist used to treat benign prostatic hyperplasia.
Trade name Uroxatral
Bioavailability of 49%.
Protein binding 82%-90%.
Metabolism Hepatic CYP3A4-mediated.
Biological half-life 10 hours.
Excretion is fecal (69%) and renal (24%) modes.
A drug of the alpha-1 blocker class.
As an antagonist of the alpha-1 adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.
Used to treat benign prostatic hyperplasia (BPH).
The most common side effects are dizziness, which is due to postural hypotension, upper respiratory tract infection, headache, and fatigue and abdominal disturbances.
Should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.
10 mg extended dose after a meal daily.